This review set off to make and test a solid lipid nanoparticle (SLN) formulation of zotepine (ZT) with the expectation of expanding its oral bioavailability. ZT, an enemy of crazy prescription, is recommended to patients who experience the ill effects of schizophrenia. It could be taken orally or intravenously right now. Nonetheless, because of its frail water dissolvability and the first-pass influence, ZT has an unfortunate oral bioavailability of around 7-13%. The homogenization procedure was utilized to make ZT-SLNs, which were then assessed utilizing physicochemical highlights and in vitro delivery to decide the most ideal framework. Z-avg, PDI, and ZP for the best of the created ZT-SLN formulations (F1) were 104.3 1.6 nm, 0.17 0.01, and 30.5 2.5 mV, separately. Investigations of medication delivery and pervasion in vitro showed a 48-hour arrival of 82.9% 1.6% and a 120-minute entrance of 19.6% 2.1%. The change of ZT into a formless state was identified by DSC and XRD examinations. SEM examination affirmed the ZT-SLN formulation's circular shape and high PDI. AUC was expanded by almost 1.3-crease contrasted with ZT-CS in PK tests performed on Wistar rodents (p 0.05).